Evidence map›Paper›PMID 26296477›Full record

ArticleBioorganic & medicinal chemistry letters2015

7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituent.

Vassilios Bavetsias, Yolanda Pérez-Fuertes, Patrick J McIntyre, Butrus Atrash, Magda Kosmopoulou, Lisa O'Fee, Rosemary Burke, Chongbo Sun, Amir Faisal, Katherine Bush and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Vassilios BavetsiasCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, United Kingdom. Electronic address: vassilios.bavetsias@icr.ac.uk.
Yolanda Pérez-FuertesCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, United Kingdom.
Patrick J McIntyreUniversity of Leicester, Department of Biochemistry, Lancaster Road, Leicester LE1 9HN, United Kingdom.
Butrus AtrashCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, United Kingdom.
Magda KosmopoulouDivision of Structural Biology, The Institute of Cancer Research, London, United Kingdom.
Lisa O'FeeCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, United Kingdom.
Rosemary BurkeCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, United Kingdom.
Chongbo SunCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, United Kingdom.
Amir FaisalCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, United Kingdom.
Katherine BushCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, United Kingdom.
Sian AveryCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, United Kingdom.
Alan HenleyCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, United Kingdom.
Florence I RaynaudCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, United Kingdom.
Spiros LinardopoulosCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, United Kingdom; Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research, London, United Kingdom.
Richard BaylissUniversity of Leicester, Department of Biochemistry, Lancaster Road, Leicester LE1 9HN, United Kingdom; Division of Structural Biology, The Institute of Cancer Research, London, United Kingdom. Electronic address: richard.bayliss@leicester.ac.uk.
Julian BlaggCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, United Kingdom. Electronic address: julian.blagg@icr.ac.uk.
Institute of Cancer Research · GBCancer Research UK · GBUniversity of Leicester · GB

Funding

Cancer Research UK 11566Cancer Research UK 16006Cancer Research UK C309/A11566Cancer Research UK C309/A8274Medical Research Council MR/K016903/1
6 · The paper itself

Abstract

Introduction of a 1-benzyl-1H-pyrazol-4-yl moiety at C7 of the imidazo[4,5-b]pyridine scaffold provided 7a which inhibited a range of kinases including Aurora-A. Modification of the benzyl group in 7a, and subsequent co-crystallisation of the resulting analogues with Aurora-A indicated distinct differences in binding mode dependent upon the pyrazole N-substituent. Compounds 7a and 14d interact with the P-loop whereas 14a and 14b engage with Thr217 in the post-hinge region. These crystallographic insights provide options for the design of compounds interacting with the DFG motif or with Thr217.

Indexed as

AnimalsAurora KinasesCell Line, TumorCell ProliferationCrystallizationDose-Response Relationship, DrugHumansImidazolesMiceMicrosomes, LiverModels, MolecularMolecular StructureProtein Kinase InhibitorsPyrazolesPyridinesStructure-Activity RelationshipAurora KinasesImidazolesProtein Kinase InhibitorsPyrazolesPyridinesAurora-AAurora kinaseImidazo[4,5-b]pyridine

Identifiers

PMID26296477
PMCPMC4577729
OpenAlexW2073478279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.